# Corporate Update and Third Quarter 2022 Financial Results

**Zymeworks Inc.**

November 8, 2022

**NYSE: ZYME**

www.zymeworks.com

# Forward-Looking Statements

This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this presentation and the accompanying oral statements include, but are not limited to, statements that may relate to implementation of our strategic priorities and meeting expected timelines; development of our product candidates; related clinical trials and preclinical studies; anticipated data presentations and the timing thereof; potential therapeutic effects of zanidatamab and our other product candidates; expected financial performance and future financial position; the commercial potential of technology platforms and product candidates; anticipated continued receipt of revenue from existing and future partners; our preclinical and early stage pipeline and the advancement of such pipeline; anticipated sufficiency of cash resources and other potential sources of cash to fund our planned operations; our ability to execute new collaborations and partnerships; advancement of zanidatamab zovodotin into registrational studies and other product candidates in clinical studies; our ability to satisfy potential regulatory and commercial milestones with existing and future partners; anticipated benefits of our agreement with Jazz Pharmaceuticals; our anticipated cash runway following closing of the agreement with Jazz Pharmaceuticals; the commercial potential of zanidatamab and our and Jazz Pharmaceuticals’ ability to obtain regulatory approval of and successfully commercialize zanidatamab; the anticipated timing of closing of our agreement with Jazz Pharmaceuticals and satisfaction of closing conditions; the timing and status of ongoing and future studies and the related data; the timing of and results of interactions with regulators; and other information that is not historical information. Forward-looking statements can often be identified by the use of terminology such as “subject to,” “anticipate,” “plan,” “expect,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including without limitation: clinical trials may not demonstrate safety and efficacy of any our or our collaborators’ product candidates; any of our or our partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; our assumptions regarding our financial condition or future financial performance may be incorrect; we may not be able to maintain or enter into new partnerships or strategic collaborations; we may not be able to achieve additional milestones and receive related payments and royalties from existing or future collaborations; we may not be able to obtain clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and satisfy the other terms and conditions of the transactions contemplated by the License and Collaboration Agreement between us and Jazz Pharmaceuticals; the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; and other factors described in the "Risk Factors" and other sections of our public filings with the Securities and Exchange Commission and Canadian securities regulators.

These forward-looking statements are made only as of the date hereof, and Zymeworks Inc. undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.



zymeworks

# Neil Klompas

**President & Chief Operating Officer**

# Third Quarter 2022 Financial Results

| In millions USD | 3Q21 | 3Q22 |
|---|---|---|
| Revenue | $4.4 | $2.6 |
| R&D Expense | $49.9 | $37.1 |
| G&A Expense | $15.5 | $15.9 |
| Net Loss | ($60.6) | ($47.8) |
| Cash Resources[1] | $307.8 | $166.2 |

- **Revenue** in 2022 related to research support and other payments from our partners
- **R&D expense** decrease primarily related to a reduction in employee headcount due to restructuring program and decrease in zanidatamab related manufacturing costs and clinical trial-related expenses after 2021 launch of HERIZON-GEA-01
- **G&A expense** increase driven by increase in professional fees and other expenses in 2022; partially offset by headcount reductions.
- **Cash Resources**[1] enable us to fund our planned operations into at least 2026 and, potentially beyond, subject to receipt of upfront payments[2] we anticipate receiving from the Jazz licensing agreement before the end of 2022

R&D: research and development; G&A: general and administrative; USD: United States dollar
[1] Cash resources consist of cash, cash equivalents, and short-term investments.
[2] Zymeworks is eligible to receive a $50 million upfront payment, following receipt of the clearance relating to the United States Hart-Scott Rodino Antitrust Improvements Act of 1976 (such clearance, the "HSR Clearance"), and should Jazz decide to continue the collaboration following readout of the top-line clinical data from HERIZON-BTC-01, a second, one-time payment of $325 million
Note: All financial results are as-reported for the quarters ended September 30, 2021, and September 30, 2022, respectively.

# Key Benefits to Zymeworks of Zanidatamab Licensing Agreement

- **Meaningful improvement** to **financial position** and **reduction in future expenditures** allow Zymeworks to focus on growth of exciting early-stage pipeline while zanidatamab advances to commercialization
- **Accelerate and expand R&D programs** (early R&D and ZW49) while maintaining anticipated cash runway through at least 2026 with a goal of advancing 5 new programs into clinical studies in 5 years
- **Continued management of existing zanidatamab program by Zymeworks**, in partnership with Jazz, including first BLA, leveraging existing internal expertise to progress programs rapidly, with future zanidatamab-related clinical studies, regulatory filings, and commercialization to be managed and funded by Jazz
- **Substantial potential milestone payments** based on global regulatory milestones for zanidatamab in BTC and GEA with further upside from royalties and commercial milestones
- **Leverage** Jazz's global commercial infrastructure together with BeiGene's complementary strengths in APAC regions to optimize commercialization of zanidatamab **without requirement for investment in commercial infrastructure** within Zymeworks

*Transaction allows zanidatamab to reach a broad group of patients globally and may potentially improve patient outcomes beyond the current standards of care*



APAC: Asia Pacific; BLA: biologics license application; BTC: biliary tract cancer; R&D: research and development

# ADC and Multispecific Modalities Driving Our Pipeline

## Select Difficult-to-Treat Tissue & Target


## Design with Complementary Technology Platforms




## Optionality with Two Foundational Fit-for-Purpose Modalities

### Antibody Drug Conjugates

Customization:

- Antibody properties
- Antibody format
- Payload
- DAR

### Multispecifics

Customization:

- Multiple MOA in single molecule
- Synergistic biology
- Precision targeting through multivalency

***Goal of 5 New INDs in 5 years***

ADC: antibody drug conjugate; DAR: drug to antibody ratio; Fc: fragment crystallizable region of antibody; IND: investigational new drug application; ISAC: Immunostimulatory Drug Conjugate; MOA: mechanism of action



zymeworks

# Zymeworks' Preclinical Assets Show Significant Near-Term Potential









| | | | | |
|---|---|---|---|---|
| **Target** | **MSLN x CD3** | **FRα** | **GPC3** | **NaPi2b** |
| **Format/ Technology** | 2 x 1 multispecific/ Azymetric™ heterodimeric Fc | Monospecific/TOPO1i ADC | Monospecific/TOPO1i ADC | Monospecific/TOPO1i ADC |
| **Potential Indications** | Ovarian cancer, pancreatic cancer, colorectal cancer | Ovarian cancer, other gynecological cancers, and other solid tumors | Liver cancer | Ovarian cancer, NSCLC |
| **Stage** | IND-Enabling | IND-Enabling | Late Discovery | Late Discovery |
| **Next Anticipated Milestone** | **IND 2024** | **IND 2024** | Pilot NHP toxicology study DAR optimization | Pilot NHP toxicology study DAR optimization |



ADC: antibody-drug conjugate; DAR: drug to antibody ratio; Fc: fragment crystallizable region of antibody; NSCLC: non-small cell lung cancer; NHP: non-human primate

# Upcoming Zanidatamab Clinical Catalysts

## Gastroesophageal

### Phase 1 Monotherapy (4L+)




### Phase 1 Chemo Combo (3L+)




### Phase 2 Chemo Combo (1L)

***1H 2023[1]***

### Phase 2 Tisle + Chemo Combo (1L)




## Breast Cancer

### Phase 1 Monotherapy (Late-Line)




### Phase 1 Chemo Combo (3L+)




### Phase 2 CDK4/6 Combo (3L+)

***4Q 2022[2]***

### Phase 2 Chemo Combo (1L)




## BTC & Others

### Other Cancers: Phase 1 Monotherapy (Late-Line)

***4Q 2022[3]***

### BTC: Phase 1 Monotherapy (2L+)



### BTC: Phase 2 Chemo Combo (1L)

***Currently Enrolling***

### BTC: Phase 2 Registrational Trial (2L)

***4Q 2022[4]***

Breast Cancer: Phase 1 Monotherapy (Late-Line), Phase 1 Chemo Combo (3L+), Phase 2 Chemo Combo (1L)
Other Solid Tumor: BTC Phase 1 Monotherapy (2L+), Others: Phase 1 Monotherapy (Late-Line)

[1] Updated data, initially presented at ESMO in 2021, is anticipated to be presented in the first half of 2023 [2] Data anticipated to be presented in the fourth quarter 2022; [3] Manuscript anticipated to be published in the fourth quarter 2022; [4] Topline data expected to read out 4Q22



zymeworks

# Zanidatamab Zovodotin: Differentiated HER2-Targeted ADC



## Zanidatamab zovodotin

has shown single-agent activity in multiple tumor types with a differentiated tolerability profile amongst other HER2-targeted ADCs and has multiple pathways for development

**Non-Small Cell Lung Cancer (NSCLC)**

HER2-amplified, -expressing, and -mutated

**Metastatic Breast Cancer (mBC)**

HER2-positive mBC after previous treatment with T-DXd

HER2-low mBC

**Gastroesophageal Adenocarcinoma (GEA)**

Previously treated HER2-positive GEA

**Other HER2-expressing Tumors**

Ovarian, endometrial, bladder

### DIFFERENTIATED STRATEGY

**Differentiated tolerability profile** with no interstitial lung disease, no significant neuropathy, and no significant neutropenia noted to date

**Single-agent activity** across multiple HER2-expressing tumor types

**Potential combinability with standards of care** across indications, with no known overlapping toxicities

**Incrementally staged investment** in clinical development to **preserve and maintain** cash runway



Phase 1 data (NCT03821233) as reported at ESMO | Sep 2022

# Key Strategic Priorities for 2022 and 2023

| KEY STRATEGIC PRIORITIES | STATUS / TARGET |
|---|---|
| **Financial** | |
| Reduction in workforce | ✓ |
| Improve financial position | ✓ |
| Monetize existing financial and preclinical assets | Ongoing |
| **Clinical** | |
| Fully recruit HERIZON-BTC-01 pivotal trial | ✓ |
| Fully recruit HERIZON-GEA-01 pivotal trial | YE 2023 |
| Complete/close out early-stage clinical studies | Ongoing |
| Release data and communicate development path for ZW49 | ✓ |
| **Preclinical and Platforms** | |
| Update on progress of early-stage R&D programs | ✓ |
| Advance two new product candidates to IND stage | IND by YE 2024 |
| **Partnerships & Collaborations** | |
| Global Zanidatamab licensing agreement (ex APAC) | ✓ |
| Continued execution on new partnerships and collaborations | Ongoing |

- Priority is to **reset** and **focus** the company on maximizing shareholder value and optimizing patient outcomes
- **Identify** future development paths for zanidatamab zovodotin (ZW49), ZW171, and ZW191
- **Aggressively pursue** and **drive value** through partnerships and collaborations
- **Continually improve financial position** through non-dilutive funding sources and partnerships



zymeworks

# Q&A

**Kenneth Galbraith**
Chair and CEO

**Neil Klompas**
President and COO

**Neil Josephson, MD**
CMO

**Chris Astle, PhD**
SVP and CFO

**Paul Moore, PhD**
CSO